Hocher B Pasch A 2017 BACKGROUND Chronic kidney disease-mineral and bone disorder (CKD-MBD) patients have a huge morbidity and mortality. Only relatively minor progress in therapeutic strategies has been made in the past decades. This is at least partially due to a lack of predictive diagnostic tools allowing personalized treatment of CKD-MBD patients. SUMMARY In this review we describe recent progress in the diagnosis of disturbances of calcium and phosphate metabolism in patients with CKD-MBD, measuring biological active nonoxidized parathyroid hormone as well as the overall likelihood of a patient to get calcified. KEY MESSAGE There is hope. The new tools have the potential of allowing personalized therapy for the treatment of CKD-MBD and hence improving outcome. application/pdf https://sonar.ch/global/documents/165658 eng info:eu-repo/semantics/altIdentifier/doi/10.1159/000477244 info:eu-repo/semantics/altIdentifier/pmid/28785559 info:eu-repo/semantics/openAccess Kidney diseases (Basel, Switzerland). - 2017 Biomarker Calcification propensity Chronic kidney disease-mineral and bone disorder Morbidity Mortality Nonoxidized parathyroid hormone T50 test Hope for CKD-MBD Patients: New Diagnostic Approaches for Better Treatment of CKD-MBD. http://purl.org/coar/resource_type/c_6501